Latest filings (excl ownership)
10-Q
2024 Q1
Quarterly report
9 May 24
8-K
Mineralys Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
9 May 24
EFFECT
Notice of effectiveness
12 Apr 24
424B5
Prospectus supplement for primary offering
11 Apr 24
ARS
2023 FY
Annual report to shareholders
9 Apr 24
DEFA14A
Additional proxy soliciting materials
9 Apr 24
DEF 14A
Definitive proxy
9 Apr 24
8-K
Departure of Directors or Certain Officers
4 Apr 24
S-3/A
Shelf registration (amended)
29 Mar 24
8-K
Mineralys Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
21 Mar 24
S-3
Shelf registration
21 Mar 24
10-K
2023 FY
Annual report
21 Mar 24
8-K
Mineralys Therapeutics Announces $120 Million Private Placement Financing
8 Feb 24
8-K
Mineralys Therapeutics Appoints Minji Kim, Ph.D. as Chief Business Officer
4 Jan 24
8-K
Mineralys Therapeutics Announces First Subject Dosed in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension
22 Dec 23
8-K
Regulation FD Disclosure
13 Nov 23
10-Q
2023 Q3
Quarterly report
7 Nov 23
8-K
Mineralys Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
7 Nov 23
8-K
Regulation FD Disclosure
2 Nov 23
8-K
Departure of Directors or Certain Officers
14 Sep 23
10-Q
2023 Q2
Quarterly report
7 Aug 23
8-K
Mineralys Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
7 Aug 23
8-K
Regulation FD Disclosure
17 Jul 23
10-Q
2023 Q1
Quarterly report
15 May 23
8-K
Mineralys Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
15 May 23
8-K
Other Events
2 May 23
8-K
Departure of Directors or Certain Officers
21 Mar 23
10-K
2022 FY
Annual report
15 Mar 23
8-K
Mineralys Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
15 Mar 23
SEC STAFF
SEC staff action: Order
15 Feb 23
8-K
Amendments to Articles of Incorporation or Bylaws
14 Feb 23
S-8
Registration of securities for employees
10 Feb 23
424B4
Prospectus supplement with pricing info
10 Feb 23
EFFECT
Notice of effectiveness
10 Feb 23
S-1MEF
Registration of additional securities for an S-1
9 Feb 23
CERT
Certification of approval for exchange listing
9 Feb 23
CORRESP
Correspondence with SEC
7 Feb 23
CORRESP
Correspondence with SEC
7 Feb 23
8-A12B
Registration of securities on exchange
6 Feb 23
S-1/A
IPO registration (amended)
2 Feb 23
Latest ownership filings
4
David Malcom Rodman
15 May 24
4
David Malcom Rodman
10 May 24
144
Notice of proposed sale of securities
9 May 24
4
David Malcom Rodman
15 Apr 24
4
David Malcom Rodman
13 Mar 24
4
David Malcom Rodman
15 Feb 24
4
Adam Scott Levy
15 Feb 24
4
Jon Congleton
15 Feb 24
SC 13G
TCG Crossover GP II, LLC
15 Feb 24
4
SRINIVAS AKKARAJU
14 Feb 24
4
Change in insider ownership
14 Feb 24
4
Peter Kolchinsky
14 Feb 24
SC 13G
ADAMS STREET PARTNERS LLC
14 Feb 24
SC 13G
Catalys Pacific Fund, LP
13 Feb 24
SC 13G
HBM Healthcare Investments (Cayman) Ltd.
13 Feb 24
4
David Malcom Rodman
13 Feb 24
SC 13D/A
RA CAPITAL MANAGEMENT, L.P.
12 Feb 24
SC 13D/A
Samsara BioCapital, L.P.
12 Feb 24
4
David Malcom Rodman
12 Jan 24
4
David Malcom Rodman
12 Dec 23
4
Jon Congleton
27 Nov 23
4
David Malcom Rodman
14 Nov 23
4
David Malcom Rodman
7 Nov 23
3
Daphne Karydas
14 Sep 23
4
Daphne Karydas
14 Sep 23
4
GLENN SBLENDORIO
14 Sep 23
3
GLENN SBLENDORIO
14 Sep 23
4
Jon Congleton
8 Sep 23
4
Jon Congleton
21 Aug 23
4
David Malcom Rodman
11 Aug 23
4
Jon Congleton
11 Aug 23
144
Notice of proposed sale of securities
11 Aug 23
144
Notice of proposed sale of securities
10 Aug 23
4
Takeshi Takahashi
14 Jul 23
4
Brian Taylor Slingsby
14 Jul 23
4
Olivier Litzka
1 May 23
4
David Malcom Rodman
21 Mar 23
4
Jon Congleton
21 Mar 23
4
Adam Scott Levy
21 Mar 23
SC 13D
RA CAPITAL MANAGEMENT, L.P.
24 Feb 23